Business Context and Reporting Period
This Form 8-K Current Report was filed by RXi Pharmaceuticals Corporation (referred to as Phio Pharmaceuticals Corp. in metadata) on October 5, 2018, covering events occurring on October 1 and October 3, 2018. The filing details the entry into a Material Definitive Agreement for a registered public offering of equity securities.
Key Financial Metrics and Transaction Details
The Company completed a public offering consisting of Units and Pre-Funded Units. Key financial terms include:
- Units Sold: 3,725,714 Units at $0.70 per Unit.
- Pre-Funded Units Sold: 17,702,858 Pre-Funded Units at $0.69 per Unit.
- Total Units Offered: 21,428,572 units.
- Net Proceeds: Approximately $13.3 million (after underwriting discounts, commissions, and estimated expenses).
- Underwriter Warrants: Issued to purchase up to 1,607,143 shares at an exercise price of $0.875 per share.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Transaction Structure
The primary material change is the significant increase in capitalization and potential share count due to the offering. The transaction structure included:
- Units: Each consisted of one share of Common Stock and one Warrant to purchase one share of Common Stock.
- Pre-Funded Units: Sold to purchasers who would otherwise exceed a 4.99% beneficial ownership threshold. Each consisted of one Pre-Funded Warrant (exercisable at $0.01) and one Warrant.
- Warrant Terms: Warrants included in the Units and Pre-Funded Units are immediately exercisable at $0.70 per share and expire seven years from issuance.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to use substantially all net proceeds primarily for the development of the Company's immuno-oncology program, other research and development activities, and general working capital.
Risks and Contingencies: The Underwriting Agreement contains customary representations, warranties, and indemnification provisions. The filing notes that the descriptions of the securities are qualified by reference to the full text of the Underwriting Agreement and warrant forms filed as exhibits.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the exercise status of the Pre-Funded Warrants, which are immediately exercisable at $0.01.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific termination provisions and conditions.
- Monitor the Company's cash burn rate relative to the $13.3 million raised to gauge runway for immuno-oncology development.
- Check for any subsequent filings regarding the exercise of the Underwriter Warrants (1,607,143 shares at $0.875).